Chelsea Counsel Co. cut its holdings in Johnson & Johnson (NYSE:JNJ) by 12.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 68,853 shares of the company’s stock after selling 9,535 shares during the period. Johnson & Johnson accounts for approximately 5.1% of Chelsea Counsel Co.’s portfolio, making the stock its 3rd biggest holding. Chelsea Counsel Co.’s holdings in Johnson & Johnson were worth $9,620,000 at the end of the most recent quarter.
Several other institutional investors have also bought and sold shares of the company. Broadleaf Partners LLC bought a new position in shares of Johnson & Johnson in the fourth quarter worth about $894,000. Stillwater Capital Advisors LLC increased its stake in Johnson & Johnson by 17.4% during the fourth quarter. Stillwater Capital Advisors LLC now owns 102,918 shares of the company’s stock valued at $14,380,000 after acquiring an additional 15,277 shares during the period. Indiana Trust & Investment Management CO increased its stake in Johnson & Johnson by 6.8% during the fourth quarter. Indiana Trust & Investment Management CO now owns 15,000 shares of the company’s stock valued at $2,096,000 after acquiring an additional 960 shares during the period. Hikari Power Ltd increased its stake in Johnson & Johnson by 2.3% during the fourth quarter. Hikari Power Ltd now owns 177,890 shares of the company’s stock valued at $24,855,000 after acquiring an additional 3,960 shares during the period. Finally, Daiwa SB Investments Ltd. increased its stake in Johnson & Johnson by 27.1% during the fourth quarter. Daiwa SB Investments Ltd. now owns 2,720 shares of the company’s stock valued at $380,000 after acquiring an additional 580 shares during the period. Institutional investors and hedge funds own 67.21% of the company’s stock.
Several equities analysts recently issued reports on JNJ shares. Credit Suisse Group set a $154.00 price target on Johnson & Johnson and gave the company a “hold” rating in a research note on Monday, January 22nd. Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, January 9th. Wells Fargo restated an “outperform” rating and set a $160.00 price target (up from $155.00) on shares of Johnson & Johnson in a research note on Friday, January 12th. Zacks Investment Research lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Tuesday, December 12th. Finally, JPMorgan Chase & Co. lowered Johnson & Johnson from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 2nd. Four analysts have rated the stock with a sell rating, nine have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Johnson & Johnson currently has a consensus rating of “Hold” and a consensus price target of $146.06.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, January 23rd. The company reported $1.74 EPS for the quarter, topping the consensus estimate of $1.72 by $0.02. The business had revenue of $20.20 billion for the quarter, compared to the consensus estimate of $20.08 billion. Johnson & Johnson had a return on equity of 29.00% and a net margin of 1.70%. Johnson & Johnson’s revenue was up 11.5% compared to the same quarter last year. During the same period in the previous year, the business earned $1.58 EPS. research analysts anticipate that Johnson & Johnson will post 8.11 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th were issued a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.69%. The ex-dividend date of this dividend was Monday, February 26th. Johnson & Johnson’s payout ratio is currently 861.54%.
In other news, VP Paulus Stoffels sold 155,342 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $129.86, for a total value of $20,172,712.12. Following the transaction, the vice president now directly owns 357,906 shares of the company’s stock, valued at approximately $46,477,673.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.19% of the stock is owned by insiders.
TRADEMARK VIOLATION NOTICE: “Johnson & Johnson (JNJ) Shares Sold by Chelsea Counsel Co.” was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3301311/johnson-johnson-jnj-shares-sold-by-chelsea-counsel-co.html.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.